2020 ECMM/ISHAM 共识:COVID-19相关肺曲霉病的定义与管理
该共识由专家制定并获医学真菌学会认可,提出基于样本有效性将COVID-19相关肺曲霉病定义为可能、 probable 或确诊,并推荐伏立康唑或艾沙康唑为一线治疗,若担忧唑类耐药则首选脂质体两性霉素B。
要点
- 基于样本有效性将CAPA定义为可能、probable或确诊。
- 一线治疗推荐伏立康唑或艾沙康唑。
- 若担忧唑类耐药,首选脂质体两性霉素B。
核心结论
- 提出COVID-19相关肺曲霉病的可能、probable和确诊定义,并给出诊断与治疗推荐。
研究设计与样本
- 共识声明由专家制定,获医学真菌学会认可。
主要发现
- SARS-CoV-2直接损伤气道上皮,使曲霉易于侵袭。
- 已有报道显示COVID-19相关肺曲霉病可能加重病情并增加死亡率。
- 已报告首例由唑类耐药曲霉引起的COVID-19相关肺曲霉病。
关键数值与推荐
- 基于样本有效性将COVID-19相关肺曲霉病定义为可能、probable或确诊。
- 推荐一线治疗为伏立康唑或艾沙康唑。
- 若担忧唑类耐药,首选脂质体两性霉素B。
临床怎么用
- 临床可依据样本有效性对COVID-19相关肺曲霉病进行可能、probable或确诊分层。
- 一线治疗选用伏立康唑或艾沙康唑,担忧唑类耐药时选用脂质体两性霉素B。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.
引用
- Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020. PMID: 33333012. doi:10.1016/S1473-3099(20)30847-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。